Abstract
We aimed to identify predictors of inadequate response to glucocorticoid (GC) treatment in patients with polymyalgia rheumatica (PMR). We retrospectively studied 32 patients as a derivation cohort and 24 patients as a validation cohort. The patients were divided into two groups according to the response to GC treatment: GC-responders and GC-inadequate responders (GC-IRs). We compared laboratory data and bilateral shoulder ultrasound findings between the groups. Receiver operating characteristic (ROC) analysis was performed to determine the optimal cutoff value of candidate predictors of treatment response; the predictors were examined using multivariate logistic analysis. Gray-scale ultrasound findings of long head of the biceps (LHB) tenosynovitis and subacromial/subdeltoid (SAD) bursitis were scored semiquantitatively (0–3). A total gray-scale score (TGSS) was calculated as the sum of the gray-scale scores. In the derivation cohort, serum lactate dehydrogenase (LDH) levels and TGSS were significantly higher in GC-IRs than in GC-responders. On ROC analysis, the cutoff values of serum LDH levels ≥ 175 IU/ml and TGSS ≥ 5 were found to be the candidate predictors. Multivariate logistic analysis revealed an independent association of both the predictors with inadequate response to GC treatment. In the validation cohort, patients with one or both predictors exhibited a higher incidence of inadequate response to GC treatment. These findings indicate that the severities of LHB tenosynovitis and SAD bursitis evaluated using ultrasound and serum LDH levels are independent predictors of inadequate response to GC treatment in patients with PMR. Treatment adjustment based on prediction model may allow precise treatment of patients with PMR.
References
González-Gay MA, Matteson EL, Castañeda S (2017) Polymyalgia rheumatica. Lancet 390:1700–1712. https://doi.org/10.1016/S0140-6736(17)31825-1
Rovenskỳ J, Leeb B, Štvrtinová V, Imrich R (2016) Polymyalgia rheumatica and giant cell arteritis. JAMA 315:2442–2458. https://doi.org/10.1007/978-3-319-52222-7
Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B (2017) Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol 13:1–15. https://doi.org/10.1038/nrrheum.2017.142
Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Relapse in a population based cohort of patients with Polymyalgia Rheumatica (PMR). J Rheumatol 32:65–73
Albrecht K, Huscher D, Buttgereit F, Aringer M, Hoese G, Ochs W, Thiele K, Zink A (2018) Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int 38:569–577. https://doi.org/10.1007/s00296-017-3874-3
Shbeeb I, Challah D, Raheel S, Crowson CS, Matteson EL (2018) Comparable rates of glucocorticoid-associated adverse events in patients with polymyalgia rheumatica and comorbidities in the general population. Arthritis Care Res 70:643–647. https://doi.org/10.1002/acr.23320
Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG (1997) Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40:1873–1878. https://doi.org/10.1002/art.1780401022
Mazzantini M, Torre C, Miccoli M, Baggiani A, Talarico R, Bombardieri S, Di Munno O (2012) Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol 39:552–557. https://doi.org/10.3899/jrheum.110851
Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, Matteson EL, Dasgupta B (2015) Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis 74:1808–1817. https://doi.org/10.1136/annrheumdis-2015-207578
Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, Abril A, Bachta A, Balint P, Barraclough K, Bianconi L, Buttgereit F, Carsons S, Ching D, Cid M, Cimmino M, Diamantopoulos A, Docken W, Duftner C, Fashanu B, Gilbert K, Hildreth P, Hollywood J, Jayne D, Lima M, Maharaj A, Mallen C, Martinez-Taboada V, Maz M, Merry S, Miller J, Mori S, Neill L, Nordborg E, Nott J, Padbury H, Pease C, Salvarani C, Schirmer M, Schmidt W, Spiera R, Tronnier D, Wagner A, Whitlock M, Matteson EL, Dasgupta B, Against European League, Rheumatism; American College of Rheumatology (2015) 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol 67:2569–2580. https://doi.org/10.1002/art.39333
Hassan S (2018) Overview of musculoskeletal ultrasound for the clinical rheumatologist. Clin Exp Rheumatol 36:3–9
D’Agostino MA, Terslev L, Wakefield R, Østergaard M, Balint P, Naredo E, Iagnocco A, Backhaus M, Grassi W, Emery P (2016) Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission. Ann Rheum Dis 75:1902–1908. https://doi.org/10.1136/annrheumdis-2016-209646
Mandl P, Navarro-Compán V, Terslev L, Aegerter P, van der Heijde D, D’Agostino MA, Baraliakos X, Pedersen SJ, Jurik AG, Naredo E, Schueller-Weidekamm C, Weber U, Wick MC, Bakker PA, Filippucci E, Conaghan PG, Rudwaleit M, Schett G, Sieper J, Tarp S, Marzo-Ortega H, Østergaard M, European League Against Rheumatism (EULAR) (2015) EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis 74:1327–1339. https://doi.org/10.1136/annrheumdis-2014-206971
Iagnocco A, Finucci A, Ceccarelli F, Scirocco C, Rutigliano IM (2015) Musculoskeletal ultrasound in the evaluation of polymyalgia rheumatica. Med Ultrason 17:361–366. https://doi.org/10.11152/mu.2013.2066.173.aig
Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, Bachta A, Dejaco C, Duftner C, Jensen HS, Duhaut P, Poór G, Kaposi NP, Mandl P, Balint PV, Schmidt Z, Iagnocco A, Nannini C, Cantini F, Macchioni P, Pipitone N, Del Amo M, Espígol-Frigolé G, Cid MC, Martínez-Taboada VM, Nordborg E, Direskeneli H, Aydin SZ, Ahmed K, Hazleman B, Silverman B, Pease C, Wakefield RJ, Luqmani R, Abril A, Michet CJ, Marcus R, Gonter NJ, Maz M, Carter RE, Crowson CS, Matteson EL (2012) 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71:484–492. https://doi.org/10.1136/annrheumdis-2011-200329
Mackie SL, Koduri G, Hill CL, Wakefield RJ, Hutchings A, Loy C, Dasgupta B, Wyatt JC (2015) Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. RMD Open 1:e000100. https://doi.org/10.1136/rmdopen-2015-000100
Macchioni PL, Catanoso MG, Pipitone N, Boiardi L, Salvarani C (2009) Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology 48:1566–1569. https://doi.org/10.1093/rheumatology/kep286
Miceli MC, Zoli A, Peluso G, Bosello S, Gremese E, Ferraccioli G (2017) Baseline shoulder ultrasonography is not a predictive marker of response to glucocorticoids in patients with polymyalgia rheumatica: a 12-month followup study. J Rheumatol 44:241–247. https://doi.org/10.3899/jrheum.160090
Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH (1979) An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38:434–439. https://doi.org/10.1136/ard.38.5.434
Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J, Hollywood J, Hutchings A, Kyle V, Nott J, Power M, Samanta A, BSR and BHPR Standards, Guidelines and Audit Working Group (2010) BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49:186–190. https://doi.org/10.1093/rheumatology/kep303a
Mori S, Koga Y (2016) Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy. Clin Rheumatol 35:1367–1375. https://doi.org/10.1007/s10067-014-2650-y
Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA, Wakefield RJ, Working Group for Musculoskeletal Ultrasound in the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials (2001) Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 60:641–649. https://doi.org/10.1136/ard.60.7.641
Schmidt WA, Schmidt H, Schicke B, Gromnica-Ihle E (2004) Standard reference values for musculoskeletal ultrasonography. Ann Rheum Dis 63:988–994. https://doi.org/10.1136/ard.2003.015081
Cantini F, Salvarani C, Olivieri I, Niccoli L, Padula A, Macchioni L, Boiardi L, Ciancio G, Mastrorosato M, Rubini F, Bozza A, Zanfranceschi G (2001) Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 28:1049–1055
Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C (2007) Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Care Res 57:1514–1519. https://doi.org/10.1002/art.23095
Jiménez-Palop M, Naredo E, Humbrado L, Medina J, Uson J, Francisco F, García-Yebenes MJ, Garrido J (2010) Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica. Ann Rheum Dis 69:879–882. https://doi.org/10.1136/ard.2009.113555
Huwart A, Garrigues F, Jousse-Joulin S, Marhadour T, Guellec D, Cornec D, Gouillou M, Saraux A, Devauchelle-Pensec V (2018) Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab. Arthritis Res Ther 20:11. https://doi.org/10.1186/s13075-017-1499-2
International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265. https://doi.org/10.1182/blood-2003-12-4434
Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S (2015) Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol (Madr) 54:961–970. https://doi.org/10.3109/0284186x.2015.1043026
Gallo M, Sapio L, Spina A, Naviglio D, Calogero A, Naviglio S (2015) Lactic dehydrogenase and cancer: an overview. Front Biosci (Landmark Ed) 20:1234–1249. https://doi.org/10.1016/j.ejor.2012.05.046
Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, Montecucco C, Systemic Vasculitis Study Group of the Italian Society for Rheumatology (2004) Prednisone plus Methotrexate for Polymyalgia Rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141:493–500. https://doi.org/10.7326/0003-4819-141-7-200410050-00005
Lally L, Forbess L, Hatzis C, Spiera R (2016) Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol 68:2550–2554. https://doi.org/10.1002/art.39740
Matsui K, Maruoka M, Yoshikawa T, Hashimoto N, Nogami M, Sekiguchi M, Azuma N, Kitano M, Tsunoda S, Sano H (2017) Assessment of 2012 EULAR/ACR new classification criteria for polymyalgia rheumatica in Japanese patients diagnosed using Bird’s criteria. Int J Rheum Dis 21:497–501. https://doi.org/10.1111/1756-185X.13006
Nobunaga M, Yoshioka K, Yasuda M, Shingu M (1989) Clinical studies of polymyalgia rheumatica. A proposal of diagnostic criteria. Jpn J Med 28:452–456. https://doi.org/10.2169/internalmedicine1962.28.452
Funding
This work was supported by Japan Society for the Promotion of Science (grant number JSPS KAKENHI 16K19603).
Author information
Authors and Affiliations
Contributions
MAy and YA participated in study conception and design. MAy, SO, KM, and KN participated in data acquisition and analysis. MAy, YA, HT, YK, HM, MAk, KA, TH, and HN contributed to the interpretation of results. MAy was a major contributor in writing the manuscript. All authors read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Conflict of interest
Masahiro Ayano, Yojiro Arinobu, Hiroshi Tsukamoto, Shun-ichiro Ota, Kenta Misaki, Keisuke Nishimura, Yasutaka Kimoto, Hiroki Mitoma, Mitsuteru Akahoshi, Koichi Akashi, Takahiko Horiuchi, and Hiroaki Niiro declare that they have no conflict of interest.
Ethical approval
This study was approved by the ethics committee of the Kyushu University Hospital (approval number 2019-061), and the principles of the Helsinki Declaration were followed throughout the study. Because this was retrospective research, we disclosed the study information at the site of the related facilities. Obtaining patient consent was not required according to the committee’s procedures.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ayano, M., Arinobu, Y., Tsukamoto, H. et al. Shoulder ultrasound and serum lactate dehydrogenase predict inadequate response to glucocorticoid treatment in patients with polymyalgia rheumatica. Rheumatol Int 40, 1101–1109 (2020). https://doi.org/10.1007/s00296-020-04512-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-020-04512-9